Answers are grounded in this paper and cite their sources.
Observational study shows reduced in-hospital mortality with streptokinase in acute myocardial infarction, indicating survival benefits with early thrombolysis.
Acute myocardial infarction is the leading cause of death.Streptokinase is the most commonly used thrombolytic agent.This study was conducted to compare in-hospital outcome of patients with acute myocardial infarction receiving streptokinase with those not receiving it.About 340 patients having acute MI were included in the study.Two groups were formed.Group 1 (SK Group) receiving streptokinase and Group 2(Non SK) not receiving streptokinase.For the patient condition assessment In-hospital mortality was the primary end while mechanical and electrical complications were the secondary end points.Among 340 patients, 255(75%) were males and 85(25%) females.Out of those 218 received streptokinase, while 122 did not receive the drug The mean age of group 1 was 53.1 ±10.3 years and group 2 age was 60.5 ± 16years.Mean time of arrival to the hospital after symptom onset was 10.4 ± 9.97 h.SK group patients reached in 5.9 ± 4.7 hours while group 2 in 19.4 ± 10.5 h.In-hospital mortality in group 1 and group 2 was 19(8.7%) and 25(20.5%)respectively, (p=0.002).Complication rate was significantly higher in non-streptokinase group.Patients of acute myocardial infarction receiving streptokinase have significantly lesser in hospital mortality and complications as compared to patients not receiving it.
No takes yet. Share an insight, caveat, or question.
Shameem et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: